10.10.25 -- New FDA White Paper Ties Quality To Financial Benefits

Industry 4.0 is gaining momentum, but scaling remains a challenge. Discover why a robust industrial data strategy is essential and the top five barriers keeping manufacturers stuck in pilot purgatory.

By transitioning to alternative solvents or leveraging process aids, the challenges associated with the use of these chemicals can be addressed, helping create a sustainable, greener footprint.

Gain insights from a pharmaceutical equipment manufacturer on factors cannabis manufacturers should consider when they're looking to purchase a mixer.

Explore strategies for maximizing ROI in pharma through advanced analytics, streamlined operations and an interconnected data management platform.

Uncover the key advantages of stick-pack formats for pharmaceuticals and nutraceuticals, from enhanced product safety and cost-efficiency to improved compliance and marketability.

Vial fogging is a common phenomenon observed in lyophilized biologic drug products. Examine two case studies that review critical factors contributing to vial fogging and inform vial selection decisions.

Maintaining a cleanroom facility that remains safe for your workers – and where the therapeutics they produce remain safe for patients – can ease your compliance concerns.

Sterile injectables are vital for modern medicine. Learn how outsourcing manufacturing to a CDMO can accelerate development and commercialization.

Whether you aim to address bottlenecks or explore advanced techniques, gain a practical and forward-thinking perspective to streamline early-phase development with HTE and model-based approaches.

A highly concentrated non-aqueous suspension of an IgG1 was developed using a patented platform. See how the particle size of the mAb impacts the overall behavior of the drug product.

Next Generation Sequencing offers a sensitive, high-throughput solution for detecting adventitious viral agents to improve safety and accelerate regulatory-compliant product development.

Find out more about strategies to mitigate sticking and picking risks in the tablet industry, and how you can foster improved tablet production processes to ensure higher quality and consistency.

Partner with an experienced end-to-end CDMO to streamline development, reduce risk, and accelerate your drug’s path to market in today’s complex and competitive pharmaceutical landscape.

Accelerated development and manufacturing timelines provide developers with paths to move new therapies to market quickly while still maintaining a balance of risk/benefit assessment. 

Reconstituted nasal epithelium (RNE) offers a human-relevant model for nasal drug delivery, outperforming frozen mucosa and aligning better with clinical outcomes for opioid formulations.